Tranexamic Acid During Colonic Endoscopic Resection Procedures

Recruiting now · Phase 4

Conditions studied: Colon Neoplasm

In brief

Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.

Key facts

Study ID

NCT05345613

Run by

Assaf-Harofeh Medical Center

People needed

200

Starts

2022-05-01

Expected to finish

2026-10-01

Last updated by the study team

2026-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.
• Age > 18 years

You may not qualify if…

• patients with histories of allergic reactions to TXA
• history of seizures
• pregnancy

Where it is running

• Shamir Medical Center — Be’er Ya‘aqov, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.